[1]
|
Andrade RM, Alarcón GS, Fernández M, et al.Accelerated damage accrual among men with systemic lupus erythematosus:XLIV. Results from a multiethnic US cohort[J].Arthritis Rheum, 2007, 56:622-630. doi: 10.1002/art.22375 |
[2]
|
Thamer M, Hernan MA, Zhang Y, et al.Prednisone, lupus activity, and permanent organ damage[J].J Rheumatol, 2009, 36:560-564. doi: 10.3899/jrheum.080828 |
[3]
|
Appel GB, Contreras G, Dooley MA, et al.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis[J].J Am Soc Nephrol, 2009, 20:1103-1112. doi: 10.1681/ASN.2008101028 |
[4]
|
Ginzler EM, Dooley MA, Aranow C, et al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J].N Engl J Med, 2005, 353:2219-2228. doi: 10.1056/NEJMoa043731 |
[5]
|
Mok CC, Ying KY, Yim CW, et al.Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis:a randomised controlled trial and long-term follow-up[J].Ann Rheum Dis, 2016, 75:30-36. doi: 10.1136/annrheumdis-2014-206456 |
[6]
|
Liu Z, Zhang H, Liu Z, et al.Multitarget therapy for induction treatment of lupus nephritis:a randomized trial[J].Ann Intern Med, 2015, 162:18-26. doi: 10.7326/M14-1030 |
[7]
|
Fanouriakis A, Kostopoulou M, Alunno A, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis, 2019, 78:736-745. doi: 10.1136/annrheumdis-2019-215089 |
[8]
|
Merrill JT, Neuwelt CM, Wallace DJ, et al.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus:the randomized, double-blind, phase Ⅱ/Ⅲ systemic lupus erythematosus evaluation of rituximab trial[J].Arthritis Rheum, 2010, 62:222-233. doi: 10.1002/art.27233 |
[9]
|
Rovin BH, Furie R, Latinis K, et al.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis:the Lupus Nephritis Assessment with Rituximab study[J].Arthritis Rheum, 2012, 64:1215-1226. doi: 10.1002/art.34359 |
[10]
|
Murray E, Perry M.Off-label use of rituximab in systemic lupus erythematosus:a systematic review[J].Clin Rheumatol, 2010, 29:707-716. doi: 10.1007/s10067-010-1387-5 |
[11]
|
Navarra SV, Guzman RM, Gallacher AE, et al.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial[J].Lancet, 2011, 377:721-731. doi: 10.1016/S0140-6736(10)61354-2 |
[12]
|
Furie R, Petri M, Zamani O, et al.A phase Ⅲ, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J].Arthritis Rheum, 2011, 63:3918-3930. doi: 10.1002/art.30613 |
[13]
|
Merrill JT, Wallace DJ, Wax S, et al.Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus:Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase Ⅱb Study[J].Arthritis Rheumatol, 2018, 70:266-276. doi: 10.1002/art.40360 |
[14]
|
Isenberg D, Gordon C, Licu D, et al.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (APRIL-SLE randomised trial)[J].Ann Rheum Dis, 2015, 74:2006-2015. doi: 10.1136/annrheumdis-2013-205067 |
[15]
|
Alexander T, Sarfert R, Klotsche J, et al.The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus[J].Ann Rheum Dis, 2015, 74:1474-1478. doi: 10.1136/annrheumdis-2014-206016 |
[16]
|
Merrill JT, Shanahan WR, Scheinberg M, et al.Phase Ⅲ trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE):results from a randomised, double-blind, placebo-controlled trial[J].Ann Rheum Dis, 2018, 77:883-889. doi: 10.1136/annrheumdis-2018-213032 |
[17]
|
Onuora S.Positive results for anifrolumab in phase Ⅲ SLE trial[J].Nat Rev Rheumatol, 2020, 16:125. doi: 10.1038/s41584-020-0384-6 |
[18]
|
Khamashta M, Merrill JT, Werth VP, et al.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus:a randomised, double-blind, placebo-controlled study[J].Ann Rheum Dis, 2016, 75:1909-1916. doi: 10.1136/annrheumdis-2015-208562 |
[19]
|
Zhao J, Wang H, Dai C, et al.P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway[J].Arthritis Rheum, 2013, 65:3176-3185. doi: 10.1002/art.38174 |
[20]
|
Zhao J, Zhang H, Huang Y, et al.Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation[J].Int Immunopharmacol, 2013, 17:116-122. doi: 10.1016/j.intimp.2013.05.027 |
[21]
|
van Vollenhoven RF, Hahn BH, Tsokos GC, et al.Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus:results of a multicentre, double-blind, phase 2, randomised, controlled study[J].Lancet, 2018, 392:1330-1339. doi: 10.1016/S0140-6736(18)32167-6 |
[22]
|
He J, Zhang R, Shao M, et al.Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus:a randomised, double-blind, placebo-controlled trial[J].Ann Rheum Dis, 2020, 79:141-149. doi: 10.1136/annrheumdis-2019-215396 |
[23]
|
Wang S, Yang N, Zhang L, et al.Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice[J].Lupus, 2010, 19:1171-1180. doi: 10.1177/0961203310367660 |
[24]
|
Zhou M, Guo C, Li X, et al.JAK/STAT signaling controls the fate of CD8(+)CD103(+) tissue-resident memory T cell in lupus nephritis[J].J Autoimmun, 2020, 102424. |
[25]
|
You H, Zhang G, Wang Q, et al.Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus:the experience from a single centre[J].Ann Rheum Dis, 2019, 78:1441-1443. doi: 10.1136/annrheumdis-2019-215455 |
[26]
|
Deng GM, Liu L, Bahjat FR, et al.Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice[J].Arthritis Rheum, 2010, 62:2086-2092. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=106c5d5ff49018419011afb0e0fbfdf4 |
[27]
|
Zhao J, Wang H, Huang Y, et al.Lupus nephritis:glycogen synthase kinase 3beta promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice[J].Arthritis Rheumatol, 2015, 67:1036-1044. doi: 10.1002/art.38993 |
[28]
|
Djabarouti S, Breilh D, Duffau P, et al.Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares:an observational cohort study[J].Arthritis Res Ther, 2010, 12:R217. doi: 10.1186/ar3202 |